entertainment -WSS

entertainment

author：fashion 2025-09-30 08:51:49 - browse：4925

The building exterior of AstraZeneca, a pharmaceutical and biopharmaceutical company, under cloudless blue sky — coverage from STAT — Adobe

WILMINGTON, Del. — Wednesday was the first time that a federal judge asked questions in-person of drug industry lawyers who are trying to stop Medicare from negotiating drug prices. It didn’t go well for them.

AstraZeneca’s lawyers argued that Medicare’s new powers amount to a taking of their property rights without due process. But Colm Connolly, chief judge of the U.S. District Court of Delaware, said he doesn’t understand how the law deprives AstraZeneca of its property. He asked Catherine Stetson, who represents AstraZeneca, multiple times to explain what property the company would lose due to Medicare price negotiation. Stetson said it’s both the patent and the drug that’s subject to the patent.

“You’re free to do what you want,” Connolly said, adding that drug companies don’t have to sell to Medicare. “You may not make as much money.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Wellcome Trust names Røttingen as its new CEO

WSS

How should state employee insurance handle Wegovy?

Michigan AG announces felony charges against 'fake electors' in 2020 election plot

Grail faces three suits alleging harassment, retaliation

Care demand spikes challenge UnitedHealth’s provider arm

RFK Jr. accused of antisemitic claims about COVID but insists he was misunderstood

Medicare eyes cuts to doctors, raises to outpatient clinics in 2024

hotspot

entertainment

focus

After affirmative action ruling, medical educators look to 'holistic review'

Eight reasons why you should get an updated Covid vaccine

Medical leaders decry Supreme Court decision on affirmative action

Female surgeons have lower rates of long

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

There’s no way to know how good AI health technologies are

New air purifier tech could be key to improving indoor air quality

European regulators consider appeal over Amylyx ALS drug

DIEP, the 'gold standard' of breast reconstruction, is under threat

Mike Pence clashes with Tucker Carlson in Iowa

hotspot

Why police arrested suspected Gilgo Beach killer away from his house

UnitedHealth’s Q3 profit jumps as medical costs rise more slowly

There’s no way to know how good AI health technologies are

STAT Readout: Today's biotech news includes Sana and Amylyx

What's changing in Medicare's open enrollment this year?

Europe sees delivery challenges ahead on Alzheimer's therapies

knowledge

leisure time

focus

hotspot